Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2176 - Histopathological response to neoadjuvant chemotherapy is predictive for prognosis in locally advanced gastroesophageal cancer


08 Oct 2016


Poster Display


Silvia Spoerl


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


S. Spoerl1, S. Al-Batran2, M. Feith3, F. Lordick4, P. Thuss-Patience5, C. Pauligk2, B. Haller6, A. Novotny3, S. Lorenzen1

Author affiliations

  • 1 3rd Department Of Internal Medicine, Klinikum Rechts Der Isar, Technische Universität München, 81675 - München/DE
  • 2 Uct University Cancer Center, Nordwest-Krankenhaus, Frankfurt am Main/DE
  • 3 Department Of Surgery, Klinikum Rechts Der Isar, Technische Universität München, 81675 - München/DE
  • 4 University Cancer Center Leipzig, University Clinic Leipzig, 04103 - Leipzig/DE
  • 5 Department Of Hematology, Oncology And Tumorimmunology, Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 6 Institute For Medical Statistics And Epidemiology, Technische Universität München, 81675 - München/DE


Abstract 2176


Neoadjuvant chemotherapy (neoCTx) improves the prognosis of patients (pts) with localized esophagogastric adenocarcinoma (EGC). This retrospective analysis evaluates the predictive value of histopathology on neoCTX.


461 pts with locally advanced EGC (T2/T3 and/or N+) who received neoCTx followed by surgery between 2000 and 2013 were analyzed from four institutions: 314 (68.1%) with intestinal, 94 (20.4%) with diffuse and 53 (11.5%) with mixed histological type according to Laurens classification. Taxane-platinum-fluoropyrimidine (5FU) based triplet or platinum-FU based doublet neoCTX was administered preoperatively to 185 (40.1%) and 276 (59.9%) pts, respectively. Pathological response evaluation according to Becker was performed locally.


Median patients' age was 63 years, 79.8% were male. Tumors were localized in the stomach in 32.5% and EG junction in 67.5%. 96.5% had clinical stage T3/T4 and 93.7% were N+. With a median follow up of 39.6 months (mos), median overall survival (OS) was 66.4 mos. For pts with intestinal type, median OS was 77.9 mos compared to 34.6 mos for diffuse (p 


Pathologic complete response is associated with long-term survival in EGC independent of histopathological subtype. Efforts to increase the rate of pCR by more effective neoCTX are warranted.

Clinical trial identification

Legal entity responsible for the study

Technical University Munich


Technical University Munich


F. Lordick: Receipt of grant/research supports: GSK, Fresenius Biotech, Boehringer. Receipt of honoraria or consultation fees: Amgen, Eli Lilly, Garrymed, MSD. Merck-Serono, Roche, Taiko. Travel support: Bayer, MSD, Amgen, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings